![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer Acquisition Expected to Close Today Deal Valued at $9.7 Billion PR Newswire THOUSAND OAKS, Calif., Oct. 1, 2013 THOUSAND OAKS...
Amgen and Onyx Pharmaceuticals Announce Early Termination of HSR Waiting Period for Amgen's Acquisition of Onyx PR Newswire THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Sept. 18, 2013...
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 09/17/13 -- Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today announced the upcoming presentations of data highlighting Nexavar® (sorafenib) tablets and...
Bayer's Stivarga® (regorafenib) Tablets Approved in Europe PR Newswire WHIPPANY, N.J. and SOUTH SAN FRANCISCO, Calif., Aug. 30, 2013 WHIPPANY, N.J. and SOUTH SAN FRANCISCO, Calif., Aug...
ONYX PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Onyx Pharmaceuticals, Inc. PR Newswire NEW...
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Onyx...
The biotech space is likely to find greater focus in the wake Amgen’s (AMGN) purchase of ONXY Pharmaceuticals (ONXX). Investors looking for strong growth at a reasonable price in...
Rigrodsky & Long, P.A.: Do you own shares of Onyx Pharmaceuticals, Inc. (NASDAQ GS: ONXX)? Did you purchase any of your shares prior to August 25, 2013? Do you think the...
"Bayer, Onyx Get FDA Priority Review for Sorafenib For Type of Cancer" published at 6:29 a.m. EDT mispelled Onyx in the headline. Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions